三种来自Fissistigma oldhamii Levl.的三种新型醇类衍生物. 和它们的抗炎作用
De-Cai Dai1, Xue-Feng Xu1, Hao Yan1
1Key Laboratory of Medicinal and Edible Plants Resources of Hainan Province, Hainan Vocational University of Science and Technology, Haikou, People's Republic of China.
Fitoterapia
|March 13, 2024
概括
来自Fissistigma oldhamii根的三种新型醇类衍生物显示出强大的抗炎性质. 这些化合物有效地抑制氧化 (NO) 的产生,为开发新的天然抗炎剂提供了潜力.
科学领域:
- 自然产品化学 自然产品化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- Fissistigma oldhamii 根是一种生物活性化合物的来源.
- 印度醇类化合物以各种生物活动而闻名.
- 炎症是治疗干预的关键目标.
研究的目的:
- 从Fissistigma oldhamii中分离和表征新的类类衍生物.
- 评估隔离化合物的抗炎潜力.
- 探索F. oldhamii作为一种新型抗炎药物发现的来源.
主要方法:
- 使用色谱技术分离化合物.
- 通过综合光谱分析 (NMR,MS) 阐明结构.
- 在LPS刺激的RAW264.7细胞中抑制氧化 (NO) 生产的体外评估.
主要成果:
- 分离了三种新的醇衍生物 (fissindoalkas A-C) 和一种已知的化合物.
- 化合物2和3表现出强大的制NO生产.
- 化合物2和3的IC50值分别为2.52 ± 0.18 μM和2.33 ± 0.16 μM.
结论:
- Fissindoalkas A-C具有显著的抗炎活性.
- Fissistigma oldhamii是发现天然抗炎剂的有希望的来源.
- 这些发现支持从自然产品中提取的新疗法.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
139
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
139
Antiasthma Drugs: Leukotriene Modifiers
297
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
297
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Drugs for Treatment of Diarrhea-Predominant IBS
167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
118
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
118


